Radius Health Inc (RDUS) Receives Average Rating of “Hold” from Brokerages

Shares of Radius Health Inc (NASDAQ:RDUS) have been given an average recommendation of “Hold” by the eleven research firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $48.14.

A number of analysts have recently commented on the stock. Zacks Investment Research cut shares of Radius Health from a “buy” rating to a “hold” rating in a research note on Tuesday, December 11th. BidaskClub raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Thursday. Cowen reissued a “hold” rating on shares of Radius Health in a research note on Tuesday, November 6th. Finally, JPMorgan Chase & Co. cut their target price on shares of Radius Health from $59.00 to $52.00 and set an “overweight” rating for the company in a research note on Friday, November 2nd.

RDUS stock opened at $15.78 on Tuesday. The stock has a market cap of $718.62 million, a PE ratio of -2.72 and a beta of 1.06. The company has a debt-to-equity ratio of 1.85, a current ratio of 5.50 and a quick ratio of 5.39. Radius Health has a 52 week low of $14.52 and a 52 week high of $41.16.

Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.17. The business had revenue of $27.70 million during the quarter, compared to analysts’ expectations of $26.00 million. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. The company’s quarterly revenue was up 105.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.31) earnings per share. As a group, equities analysts anticipate that Radius Health will post -5.17 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of RDUS. Alps Advisors Inc. boosted its position in Radius Health by 10.3% during the second quarter. Alps Advisors Inc. now owns 65,973 shares of the biopharmaceutical company’s stock worth $1,944,000 after acquiring an additional 6,165 shares during the last quarter. State of Wisconsin Investment Board boosted its position in Radius Health by 7.0% during the second quarter. State of Wisconsin Investment Board now owns 41,200 shares of the biopharmaceutical company’s stock worth $1,214,000 after acquiring an additional 2,700 shares during the last quarter. Sei Investments Co. boosted its position in Radius Health by 20.9% during the second quarter. Sei Investments Co. now owns 88,078 shares of the biopharmaceutical company’s stock worth $2,595,000 after acquiring an additional 15,200 shares during the last quarter. Trexquant Investment LP acquired a new position in Radius Health during the second quarter worth about $879,000. Finally, Schwab Charles Investment Management Inc. boosted its position in Radius Health by 13.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 217,152 shares of the biopharmaceutical company’s stock worth $6,400,000 after acquiring an additional 25,642 shares during the last quarter.

About Radius Health

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.

Recommended Story: Day Trading

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply